Neprilysin inhibitors
In one aspect, the invention relates to compounds having the formula XII: where R a , R b , R 2 , R 7 , and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
1. A compound of:
(a) (2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)amino]pentanoic acid;
(b) (2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)amino]pentanoic acid 2-methoxycarbonylamino-3-methylbutyryloxymethyl ester;
(c) (2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)amino]pentanoic acid isopropoxycarbonyloxymethyl ester;
(d) (2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)amino]pentanoic acid acetoxymethyl ester;
(e) (2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)-amino]pentanoic acid ethoxycarbonyloxymethyl ester; or
a pharmaceutically-acceptable salt thereof.